FDA rejects Capricor's DMD cell therapy, citing need for more data
TL;DR
The FDA rejected Capricor Therapeutics' application for its cell therapy deramiocel aimed at treating Duchenne muscular dystrophy, citing insufficient evidence of effectiveness and requesting more clinical data.
- FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy STAT
- Capricor shares sink as US FDA declines to approve cell therapy Reuters
- FDA rejects approval of Capricor's cell therapy for DMD FirstWord Pharma
- Capricor Shares Sink After FDA Rejects Drug for Muscle Disease Bloomberg
- FDA rejects Capricor’s DMD cell therapy, asks for more data Fierce Biotech
Want the full story? Read the original reporting
Read on STAT